News
-
-
PRESS RELEASE
Ondine Biomedical Inc Announces Corporate and Trading Update
Ondine Biomedical (LON:OBI) reports significant revenue growth and commercial momentum in 2023 with doubled revenues and increased number of hospital deployments, including strategic inroads in the UK, Spain, and Australia. The company also announces distribution partnerships and plans for US Phase 3 Clinical Trial -
-
-
-
PRESS RELEASE
KALRAY ACHIEVES SIGNIFICANT IMPROVEMENT IN 2023 ANNUAL RESULTS
Kalray (Euronext Growth Paris: ALKAL) announces strong financial results for 2023, with consolidated revenue up 57% to €25.8 million, gross margin at 67%, and significant EBITDA improvement. Strategic collaborations with Arm in the AI market show promising growth potential -
-
-
-